Polynucleotides: what the molecule is

What is in the syringe

Polynucleotide products are described by their manufacturers as highly purified polymers of nucleotides, typically obtained from fish sources, fragmented to a defined chain length range and sterilised. Fish sourcing is chosen on grounds of availability and the argument that the resulting material is highly conserved and therefore poorly immunogenic. The product presents as a viscous gel.

Two things are worth noticing immediately. First, this is a purified biological polymer, not a cell-derived signalling preparation, which puts it in a different part of the family from vesicle and platelet products despite frequently appearing alongside them. Second, chain length distribution is a manufacturing specification that materially affects both viscosity and any proposed biological activity, and it is rarely disclosed in a form that permits comparison between products.

The physical mechanism

A long-chain polymer gel injected into dermis occupies space, binds water and provides a temporary scaffold. This is uncontroversial and it is the same category of effect claimed for hyaluronic acid skin boosters, discussed in skin boosters and what they are not. It would be expected to produce a hydration and turgor effect that persists while the material persists and resolves as it is broken down.

If this were the whole story, polynucleotides would be a skin booster with a different polymer, and the interesting questions would be duration, injection comfort and adverse event profile. The market does not present them that way.

The biological mechanisms proposed

Three biological arguments recur, and they are not equally strong.

Nucleotide salvage

The claim is that fragmented nucleic acid is broken down locally to nucleotides that neighbouring cells take up and use, supporting proliferation and matrix synthesis. Nucleotide salvage pathways are real biochemistry. Whether cells in dermis are meaningfully limited by nucleotide availability, such that supplying more changes their behaviour, is the step the argument needs and does not obviously have.

Receptor-mediated signalling

The claim is that nucleic acid fragments engage cell surface or intracellular receptors that respond to nucleic acid, producing a signalling effect. Such receptors exist, mainly as part of innate immune sensing. Engaging them is not automatically desirable, since their normal role is to detect foreign nucleic acid and mount a response. An account that proposes this mechanism owes an explanation of why the resulting response is beneficial rather than inflammatory.

Scaffold and matrix interaction

The claim is that the gel provides a physical environment favourable to fibroblast activity. This is the most modest claim and the most plausible, and it is close to the physical mechanism rather than distinct from it.

Injected polynucleotides stimulate fibroblast activity through a biological mechanism beyond their physical presence in tissue.

Proposed mechanism

Nucleotide fragments are taken up or sensed by dermal cells, altering proliferation and matrix synthesis.

What has been shown

Laboratory work has reported effects of nucleotide-containing preparations on cultured cells. Clinical studies of polynucleotide injectables report improvements in skin quality measures. Those clinical studies generally cannot separate a biological effect of the molecule from the physical effect of injecting a viscous gel and from the effect of needle passes into dermis.

Highest level reached

Small human studies

Main confounders

The injection procedure itself provokes a dermal response. Gel volume produces immediate physical change. Assessment is often unblinded and by appearance. Chain length and concentration differ between products and are rarely reported.

GradeEARLY, UNREPLICATED

What would change thisA randomised comparison against an inert gel of matched viscosity and volume, delivered by identical technique, with blinded assessment and an objective endpoint. That design isolates the molecule from the vehicle and from the needling, and to our knowledge it is not what the available studies have done.

The comparison nobody runs

The study described in the panel above is not exotic. Vehicle-controlled trials are routine in dermatology, and the vehicle in this case is a gel of similar physical properties without the nucleic acid. The reason it is rarely run is commercial rather than technical: a positive result against no treatment supports a marketing claim adequately, and a null result against a matched vehicle would be expensive information to own.

This is worth naming plainly because it recurs across the whole family. When the confound is the vehicle and the trial has no vehicle arm, the trial cannot answer the question that the product's premium price depends on. That is a design gap, not a mystery.

Safety, sourcing and what to ask

Fish-derived material raises a reasonable question about allergy, and manufacturers address it by citing purification. A patient with a fish allergy should raise it with the practitioner, and a practitioner should be able to say what the manufacturer's position is and what the product information states. That is a matter of reading the product literature rather than of scientific controversy.

The more general questions are the ones that apply to any injected material: what is the regulatory status of this specific product in this jurisdiction, what is the adverse event profile as recorded in the product information, who is administering it, and what happens if something goes wrong. We deal with the regulatory dimension in borderline products and the MHRA.

How polynucleotides sit in the family

They occupy an interesting middle position. Unlike vesicle preparations, the material is chemically defined and can be specified precisely, which is a genuine advantage: chain length distribution, concentration and purity are measurable properties of a known molecule. Unlike hyaluronic acid boosters, a biological mechanism is claimed on top of the physical one.

That combination means the evidential question is unusually clean. The molecule can be characterised, so the ambiguity is not about what is in the syringe. It is entirely about whether the biological mechanism adds anything to the physical one. A well designed trial could answer it. Until one does, a careful reader should treat the physical effect as the supported part and the biological effect as the proposed part, and should notice that the price is set as though the second were established.

Questions readers ask

What are polynucleotide injections made of?

Purified, fragmented nucleic acid polymers, most commonly described by manufacturers as derived from fish, formulated as a sterile viscous gel for injection into skin. Chain length distribution is a manufacturing specification that affects both viscosity and any proposed biological action.

Are polynucleotides the same as exosomes?

No. Polynucleotides are a purified chemical polymer with a defined composition. Vesicle preparations are cell-derived mixtures of particles and co-isolated material. They are grouped together commercially, but they are different kinds of product with different evidential problems.

Do polynucleotides stimulate collagen?

Clinical studies report improvements in skin quality measures after treatment. Whether those improvements are caused by the nucleic acid, by the physical presence of the gel, or by the needling required to place it has not been separated by a vehicle-controlled design.

Are they safe for people with fish allergy?

This is a question for the practitioner and the product information rather than for a general article. Manufacturers address it on purification grounds. Anyone with a fish allergy should raise it explicitly before treatment.

What single study would settle the question?

A randomised trial comparing the product against an inert gel matched for viscosity and volume, injected by identical technique, with blinded assessment and an objective endpoint. That isolates the molecule from the vehicle and from the procedure.